Journal Logo

Research Article: Clinical Case Report

Dysphagia with fatal choking in oculopharyngeal muscular dystrophy

Case report

Chen, Andy Wei-Ge MDa; Wu, Shey-Lin MD, PhDb; Cheng, Wen-Ling MScc; Chuang, Chieh-Sen MD, PhDb; Chen, Chih-Hua MSca; Chen, Mu-Kuan MD, PhDa,∗; Liu, Chin-San MD, PhDb,c,d,e,∗

Editor(s): NA.,

Author Information
doi: 10.1097/MD.0000000000012935
  • Open

Abstract

1 Introduction

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset progressive muscle disorder typically characterized by ptosis, difficulty in swallowing, and proximal limb weakness.[1] The standard method of diagnosing OPMD is gene testing. OPMD is caused by the abnormal increase in the number of repeats of the alanine-encoding (GCN) trinucleotide in the PABPN1 gene.[2] The wild-type PABPN1 gene contains 10 GCN repeats, whereas affected individuals have 11 to 18 repeats.[3]

OPMD has been reported worldwide, with the highest prevalence in Bukhara Jews (1:600)[4] and French Canadians (1:1000). However, only few small cohorts have been reported in the Chinese population. Families with the (GCG)9(GCA)3GCG mutation and the (GCG)6(GCA)(GCG)4(GCA)3GCG mutation were reported by Huang et al[5] and Kuo et al.[6]

Here, we report a case of OPMD with the (GCG)10(GCA)3GCG mutation. The patient had an extensive family history of dysphagia and lethal choking events. Owing to the lack of knowledge of the disease and a greater concern about the ethical issues related to gene analysis in Asian societies, OPMD may have long been underdiagnosed in Eastern and Southeastern Asia. Dysphagia and aspiration are important issues that cannot be neglected among these patients.

2 Case presentation

A 53-year-old Taiwanese female was referred to our Otolaryngology and Neurology department because of progressive dysphagia. She had been healthy until 6 years ago, when she developed ptosis and dysphagia.

The ptosis progressed gradually, causing her to have trouble with driving. Three years ago, blepharoplasty was recommended and performed by a plastic surgeon. Two choking events with solid food recently occurred, prompting her to seek our assistance. An extensive family history of choking and dysphagia was revealed in her interview. The affected family members are shown in Figure 1, and an autosomal dominant inheritance pattern was revealed. II-1, II-4, and II-6 suffered from ptosis and received blepharoplasty. Her grandmother (I-2 in Fig. 1) and older brother (II-1 in Fig. 1) died from choking events.

Figure 1
Figure 1:
Pedigree of the family. The family tree shows the affected (black) and asymptomatic (blank) members. Squares indicate males, and circles indicate females. An autosomal dominant inheritance pattern can be seen in the pedigree. III-8 is the proband (arrow). II-4, II-6, and III-8 underwent blepharoplasty because of progressing ptosis. I-2 and II-1 died of choking events related to the disease.

The physical examination was unremarkable. Nasopharyngoscopy showed saliva pooling at bilateral pyriform sinus. Effort swallowing was observed while food intake. A video fluoroscopic swallowing study (Fig. 2) showed laryngeal vestibule invasion, indicating unsafe swallowing with a Rosenbek Penetration-Aspiration Scale score of 4. Prolonged and inefficient swallowing with pharyngeal residue at vallecula and bilateral pyriform sinus was noted while testing nectar-thickness, Honey-thickness, and Pudding-thickness materials. Poor laryngeal elevation and difficult cricopharyngeal opening were demonstrated throughout the swallowing process. Considering the clinical presentation of ptosis and dysphagia, OPMD was suspected. PABPN1 DNA Fragment Analysis[7] (Fig. 3) and sequence analysis (Fig. 4) were conducted by Applied Biosystems 3730XL DNA Analyzer. Although the wild-type PABPN1 gene at this locus should contain 2 copies of (GCG)6(GCA)3(GCG)1, the sequencing analysis revealed 1 allele with (GCG)6(GCA)3(GCG)1, and 1 allele with a mutated (GCG)10(GCA)3(GCG)1 sequence. The abnormal polyalanine expansion at PABPN1 confirmed the diagnosis of OPMD. The study was approved by the hospital's Institutional Review Board (CCH IRB No. 110407). Informed consent for publication was obtained from the patient as well.

Figure 2
Figure 2:
Results of the video fluoroscopic swallowing study. Material contact with vocal cord (black arrow) can be seen in the video fluoroscopic swallowing study before the commencement of the rehabilitation program. Much vallecular and pyriform sinus residue (white arrow) can be seen in the video clip. Upper esophageal sphincter dysfunction and poor laryngeal elevation are common findings noted in video fluoroscopic swallowing studies of OPMD patients.
Figure 3
Figure 3:
PABPN1 DNA fragment analysis. Numbers beneath each peak is the estimated size of DNA fragments. PABPN1 genotyping from the patient showed one allele with normal (GCG)6(GCA)3(GCG)1 sequence with fragment of 241.49 (241 base pair), and one allele with mutated (GCG)10(GCA)3(GCG)1 sequence, 252.94 (253 base pair), which is 12 base pair longer.
Figure 4
Figure 4:
Sequence analysis of genomic DNA. The patient's heterozygous (GCG)10(GCA)3(GCG) 1 expansion is compared with the homozygous PABPN1 gene sequence in healthy individuals. Within the red arrows are the normal (GCG)6 sequence. Note the frameshift mutation of (GCG)4 started after the red arrow in the abnormal allele.

The patient was then referred to speech language pathologists for further rehabilitation exercises. The suggested twice daily exercises were 3 repetitions of the Shaker exercise[8] and the Masako maneuver.[9] The patient's symptoms improved, and a solid diet was tolerated after 2 months of training. Because OPMD is a progressive disease, cricopharyngeal dilatation will be the next treatment choice if the dysphagia worsens.

3 Discussion

OPMD is an autosomal dominant degenerative disease caused by PABPN1 polyalanine expansion. Compared with unaffected individuals who have 10 repeats of alanine in the PABPN1 gene, affected individuals have an abnormal expansion to 11 to 18 repeats of alanine, causing misfolding of the protein and insoluble aggregation in the nucleus. Although the relationship between the PABPN1 polyalanine expansion and the symptoms of OPMD has long been questioned, a recent large cohort study[3] involving 354 patients in France demonstrated that OPMD patients with longer PABPN1 polyalanine expansions are diagnosed at an earlier age. These patients may suffer from an earlier onset of the disease and more severe symptoms than those with shorter polyalanine expansions.

A dysphagia profile investigation of OPMD patients was conducted by Tabor et al.[10] The study involved 22 OPMD patients and 124 video fluoroscopic swallowing evaluation clips, and it was determined that 86.3% of the swallows were characterized as inefficient. Vallecular residue was present in 77.3% patients, and piriform sinus residue was observed in 90.1% patients. Penetration or aspiration was noted in 33% of the swallows, leading to inadequate airway protection. A significant association between incomplete epiglottis inversion and airway safety was also demonstrated among OPMD patients. Proper exercise programs including the Shaker exercise or Mendelsohn maneuver are helpful in such circumstances by improving laryngeal lifting, cricopharyngeal opening, and epiglottis inversion. The Shaker exercise and the Masako maneuver are swallowing rehabilitation exercises that strengthen the swallowing muscles, whereas the Mendelsohn maneuver helps with swallowing food. The Mendelsohn maneuver required more muscle effort and decreases the pre-swallowing upper esophageal sphincter pressure,[11] whereas the Shaker exercise helps eliminate pharyngeal residue and decreases post-swallowing aspiration.[8] Tongue-holding exercises,[9] such as the Masako maneuver, strengthen the muscle at the base of the tongue and improves the coordination between the hyoid bone and the larynx, thereby improving pharyngeal constriction.

Currently, there is no effective treatment for OPMD-related dysphagia. Cricopharyngeal dilatation, botulinum toxin injection, and myotomy are common procedures used to treat cricopharyngeal dysfunction. Cricopharyngeal dilatation, either by bougienage or balloon, is less invasive and has been used for decades. Gradual bougination can be performed in clinics without anesthesia. More aggressive dilatation with a large-bore bougie[12] or balloon can be performed endoscopically under general anesthesia. A systematic review[13] noted that although the mean success rate of myotomy (78%) is higher than that of dilatation (73%) and that of botulinum toxin injection (69%), the difference between the success rates of myotomy and dilatation is not statistically significant. Considering the benefits of a less-invasive and more feasible procedure, dilatation can be a suitable choice for patients who cannot undergo myotomy or botulinum toxin injection.

Botulinum toxin injection has been used as a test to determine whether myotomy will be effective. Recently, it has also been used as an alternative treatment for upper esophageal sphincter dysfunction. Botulinum toxin injection can be performed under general anesthesia by transcervical surgery with endoscopic assistance. Percutaneous injection with electromyographic guidance[14] has also been reported with the benefits of local anesthesia and a shorter operating time. The dose of botulinum toxin ranges between 0∼100 units. The logistic regression analysis in the systematic review indicated that a 20-unit increase in the midpoint dose increases the odds of the success of the procedure.[13] The complication rate reported in literature reviews is, and the reported complication are mainly temporary unilateral vocal cord palsy,[14] dysphonia, or worsened dysphagia.[15]

Transcervical cricopharyngeal myotomy is the traditional surgery used to treat cricopharyngeal dysfunction. Endoscopic laser myotomy has better outcomes and fewer complications[13] than the open procedure. However, altgough myotomy is effective at releasing the contraction of the upper esophageal sphincter, it does not treat the progressive degradation of the pharyngeal muscles. Severe dysphagia, choking, and aspiration pneumonia still occur in these patients, leading to the permanent use of a nasopharyngeal tube and a feeding jejunostomy, and, ultimately, to a tracheostomy.

As the mutated PABPN1 protein with abnormally expanded alanine repeats is believed to be the key factor causing OPMD, a genetic approach targeting PABPN1 at the transcript level was reported by Malerba et al.[2] DNA-directed RNA interference, delivered by adeno-associated virus vectors, was used to completely knockdown all endogenous PABPN1 and replace it with normal PABPN1 that was resistant to that inhibition. The dual gene therapy was reported to be effective in the mouse model and in ex vivo human OPMD myoblasts. Because OPMD only involves specific skeletal muscles, it is more feasible to treat than other congenital muscular dystrophies. Gene therapy might be a novel treatment available to OPMD patients in the future.

4 Conclusion

Dysphagia is an important and potentially fatal symptom of OPMD. Underdiagnosis and a lack of awareness of OPMD may lead to choking, aspiration pneumonia, and death in multiple members in affected families. Currently, there is no definitive treatment for OPMD, but rehabilitation exercises and surgical intervention are helpful for relieving dysphagia.

Author contributions

Investigation: Mu-Kuan Chen, Chin-San Liu.

Methodology: Wen-Ling Cheng, Chih-Hua Chen.

Project administration: Chin-San Liu.

Supervision: Mu-Kuan Chen, Chin-San Liu.

Validation: Shey-Lin Wu, Chieh-Sen Chuang.

Writing – original draft: Andy Wei-Ge Chen.

Writing – review & editing: Shey-Lin Wu, Chieh-Sen Chuang, Mu-Kuan Chen, Chin-San Liu.

References

[1]. Trollet C, Gidaro T, Klein P. Adam MP, Ardinger HH, Pagon RA, et al. Oculopharyngeal muscular dystrophy. University of Washington, Seattle, GeneReviews((R)). Seattle (WA): 1993.
[2]. Malerba A, Klein P, Bachtarzi H, et al. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 2017;8:14848.
[3]. Richard P, Trollet C, Stojkovic T, et al. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology 2017;88:359–65.
[4]. Blumen SC, Nisipeanu P, Sadeh M, et al. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscular disorders: NMD 1997;7(suppl 1):S38–40.
[5]. Huang CL, Wu SL, Lai SC, et al. Oculopharyngeal muscular dystrophy—a genetically verified taiwanese family. Chang Gung Med J 2010;33:44–50.
[6]. Kuo HC, Chen CM, Lee-Chen GJ, et al. Study of a Taiwanese family with oculopharyngeal muscular dystrophy. J Neurol Sci 2009;278:21–4.
[7]. You P, Ma Q, Tao T. Gene diagnosis of oculopharyngeal muscular dystrophy in a Chinese family by a GeneScan method. J Clin Lab Anal 2010;24:422–5.
[8]. Logemann JA, Rademaker A, Pauloski BR, et al. A randomized study comparing the Shaker exercise with traditional therapy: a preliminary study. Dysphagia 2009;24:403–11.
[9]. Fujiu M, Logemann JA. Effect of a tongue-holding maneuver on posterior pharyngeal wall movement during deglutition. American Journal of Speech-Language Pathology 1996;5:23–30.
[10]. Tabor LC, Plowman EK, Romero-Clark C, et al. Oropharyngeal dysphagia profiles in individuals with oculopharyngeal muscular dystrophy. Neurogastroenterol Motil 2018;30: e13251.
[11]. Hoffman MR, Mielens JD, Ciucci MR, et al. High resolution manometry of pharyngeal swallow pressure events associated with effortful swallow and the Mendelsohn maneuver. Dysphagia 2012;27:418–26.
[12]. Clary MS, Daniero JJ, Keith SW, et al. Efficacy of large-diameter dilatation in cricopharyngeal dysfunction. Laryngoscope 2011;121:2521–5.
[13]. Kocdor P, Siegel ER, Tulunay-Ugur OE. Cricopharyngeal dysfunction: a systematic review comparing outcomes of dilatation, botulinum toxin injection, and myotomy. Laryngoscope 2016;126:135–41.
[14]. Kim MS, Kim GW, Rho YS, et al. Office-based electromyography-guided botulinum toxin injection to the cricopharyngeus muscle: optimal patient selection and technique. Ann Otol Rhinol Laryngol 2017;126:349–56.
[15]. Youssof S, Schrader RM, Romero-Clark C, et al. Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy. Muscle Nerve 2014;49:601–3.
Keywords:

dysphagia; masako maneuver; oculopharyngeal muscular dystrophy; shaker exercise

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.